AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Specialty Pharmaceutical - Worldwide Partnering Terms & Agreements, 2012 to 2018 (2019 Update) - ResearchAndMarkets.com

March 15, 2019

DUBLIN--(BUSINESS WIRE)--Mar 15, 2019--The “Global Specialty Pharmaceutical Partnering Terms and Agreements 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.

The report provides a detailed understanding and analysis of how and why companies enter Specialty Pharmaceutical partnering deals. This report provides details of the latest Specialty Pharmaceutical agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Specialty Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Specialty Pharmaceutical partnering deals.

The report presents financial deal term values for Specialty Pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Specialty Pharmaceutical partnering field; both the leading deal values and most active Specialty Pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 8,000 online deal records of actual Specialty Pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Topics Covered

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Specialty Pharmaceutical dealmaking

2.1. Introduction

2.2. Specialty Pharmaceutical partnering over the years

2.3. Most active Specialty Pharmaceutical dealmakers

2.4. Specialty Pharmaceutical partnering by deal type

2.5. Specialty Pharmaceutical partnering by therapy area

2.6. Specialty Pharmaceutical partnering by technology type

2.7. Deal terms for Specialty Pharmaceutical partnering

2.7.1 Specialty Pharmaceutical partnering headline values

2.7.2 Specialty Pharmaceutical deal upfront payments

2.7.3 Specialty Pharmaceutical deal milestone payments

2.7.4 Specialty Pharmaceutical royalty rates

Chapter 3 - Leading Specialty Pharmaceutical deals

3.1. Introduction

3.2. Top Specialty Pharmaceutical deals by value

Chapter 4 - Most active Specialty Pharmaceutical dealmakers

4.1. Introduction

4.2. Most active Specialty Pharmaceutical dealmakers

4.3. Most active Specialty Pharmaceutical partnering company profiles

Chapter 5 - Specialty Pharmaceutical contracts dealmaking directory

5.1. Introduction

5.2. Specialty Pharmaceutical contracts dealmaking directory

Chapter 6 - Specialty Pharmaceutical dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 - Specialty Pharmaceutical deals by company A-Z

Appendix 2 - Specialty Pharmaceutical deals by stage of development

Appendix 3 - Specialty Pharmaceutical deals by deal type

Appendix 4 - Specialty Pharmaceutical deals by therapy area

Appendix 5 - Deal type definitions

Table of Figures

Figure 1: Specialty Pharmaceutical partnering since 2012

Figure 2: Active Specialty Pharmaceutical dealmaking activity since 2012

Figure 3: Specialty Pharmaceutical partnering by deal type since 2012

Figure 4: Specialty Pharmaceutical partnering by disease type since 2012

Figure 5: Specialty Pharmaceutical partnering by technology type since 2012

Figure 6: Specialty Pharmaceutical deals with a headline value

Figure 7: Specialty Pharmaceutical deals with an upfront value

Figure 8: Specialty Pharmaceutical deals with a milestone value

Figure 9: Specialty Pharmaceutical deals with a royalty rate value

Figure 10: Top Specialty Pharmaceutical deals by value since 2012

Figure 11: Most active Specialty Pharmaceutical dealmakers since 2012

Figure 12: Online partnering resources

Figure 13: Forthcoming partnering events

For more information about this report visit https://www.researchandmarkets.com/research/lks8kd/specialty?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190315005125/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Pharmaceuticals

KEYWORD:

INDUSTRY KEYWORD: PROFESSIONAL SERVICES CONSULTING

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/15/2019 05:32 AM/DISC: 03/15/2019 05:32 AM

http://www.businesswire.com/news/home/20190315005125/en